Japan Pharmaceutical Companies Release Their Own "Sunshine" Data

The Japanese pharmaceutical industry has been tracking and reporting transfers of value to healthcare professionals and academic centers based in Japan. In this article, we walk through the provisions of the Japanese transparency guideline before looking at the payment data and corresponding news stories surrounding the recent release of that data. JPMA Transparency Code The Japanese Pharmaceutical Manufacturers (JPMA) approved the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions,” in 2011. The voluntary code states that JPMA member companies and member companies’ affiliates based in Japan will track their payments to medical institutions and healthcare professionals whose primary place of practice is in Japan. The code requires tracking of five categories of payments: (1) R&D expenses: joint research, research commissioning, clinical study, post-marketing study, post-marketing surveillance, and expenses incurred for adverse drug reaction/infection case reporting, reported on annual total amount (2) Academic research support expenses: scholarships to medical schools, donations to academic societies for supporting conferences, and expenses of co-sponsored conference with academic societies, reported at the university and society level (3) Honoraria: lecture fees, manuscript writing, supervising fee, consulting/ commission fee, reported at the individual physician and university level (4) Medical Seminars and Education: lectu...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs